2021
Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy
Farsky PS, White J, Al-Khalidi HR, Sueta CA, Rouleau J, Panza J, Velazquez E, O'Connor C, Investigators W, Dabrowski R, Djokovic L, Drazner M, Haddad H, Ali I, Keltai M, Naik A, Sopko G, Golba K, Andersson B, Carson P, Kukulski T. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. Journal Of Thoracic And Cardiovascular Surgery 2021, 164: 1890-1899.e4. PMID: 33610365, PMCID: PMC8260609, DOI: 10.1016/j.jtcvs.2020.12.094.Peer-Reviewed Original ResearchConceptsOptimal medical therapyCoronary artery bypassMedical therapyArtery bypassIschemic cardiomyopathyCause mortalityIschemic Heart Failure (STICH) trialVentricular ejection fraction 35Improved long-term survivalEjection fraction 35Angiotensin receptor blockersHeart Failure TrialLower cardiovascular mortalityMultivariable Cox modelOutcomes of patientsVentricular ejection fractionCoronary artery diseaseLong-term outcomesLong-term survivalSurgical revascularizationReceptor blockersCardiovascular mortalityAntiplatelet drugsArtery diseaseEjection fraction
2018
Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization
Piña IL, Zheng Q, She L, Szwed H, Lang IM, Farsky PS, Castelvecchio S, Biernat J, Paraforos A, Kosevic D, Favaloro LE, Nicolau JC, Varadarajan P, Velazquez EJ, Pai RG, Cyrille N, Lee KL, Desvigne-Nickens P. Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization. Circulation 2018, 137: 771-780. PMID: 29459462, PMCID: PMC5896331, DOI: 10.1161/circulationaha.117.030526.Peer-Reviewed Original ResearchConceptsIschemic left ventricular dysfunctionLeft ventricular dysfunctionCause mortalityCardiovascular mortalitySTICH trialSurgical deathsVentricular dysfunctionCardiovascular hospitalizationRisk factorsKansas City Cardiomyopathy Questionnaire overall summary scoreHigher New York Heart Association classCardiac Operative Risk Evaluation scoreCoronary artery disease risk factorsNew York Heart Association classHigher body mass indexComposite of deathCoronary artery bypassIschemic heart failureDisease risk factorsPoor prognostic factorVentricular ejection fractionCoronary artery diseaseBody mass indexLong-term outcomesOverall summary score
2016
Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, Hill JA, Lee KL, Rouleau JL, Prior DL, Ali IS, Maddury J, Golba KS, White HD, Carson P, Chrzanowski L, Romanov A, Miller AB, Velazquez EJ. Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation 2016, 134: 1314-1324. PMID: 27573034, PMCID: PMC5089908, DOI: 10.1161/circulationaha.116.024800.Peer-Reviewed Original ResearchConceptsCoronary artery bypassCause mortalityMedical therapyCardiovascular mortalityYounger patientsEjection fractionHeart failureCABG groupArtery bypassOlder patientsCardiovascular hospitalizationBenefit of CABGEfficacy of CABGCardiopulmonary bypass timeReduced ejection fractionVentricular systolic dysfunctionBaseline ejection fractionCoronary artery diseaseEffect of CABGTen-year outcomesConsistent beneficial effectsMore comorbiditiesSTICH trialBypass timeCardiovascular death
2015
Current and emerging modalities for detection of cardiotoxicity in cardio-oncology
Khouri MG, Klein MR, Velazquez EJ, Jones LW. Current and emerging modalities for detection of cardiotoxicity in cardio-oncology. Future Cardiology 2015, 11: 471-484. PMID: 26235924, PMCID: PMC5558528, DOI: 10.2217/fca.15.16.Peer-Reviewed Original ResearchConceptsEarly detectionLife-saving cancer therapyCurative-intent therapyCancer-specific mortalityCancer-specific survivalCardiovascular risk factorsDetection of cardiotoxicityFunctional capacity testingNovel adjuvant therapyDegree of cardiotoxicityAdjuvant therapyCardiovascular morbidityCardiovascular mortalityCardiovascular dysfunctionCardiovascular injuryBlood biomarkersRisk factorsEarly preventionCancer treatmentCardiotoxicityTherapyMortalityCancer therapyDiagnostic toolInjury
2008
Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both
Prisant LM, Thomas KL, Lewis EF, Huang Z, Francis GS, Weaver WD, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. Journal Of The American College Of Cardiology 2008, 51: 1865-1871. PMID: 18466801, DOI: 10.1016/j.jacc.2007.12.050.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBiomarkersBlack or African AmericanCaptoprilFemaleHeart FailureHospitalizationHumansIncidenceMaleMiddle AgedMyocardial InfarctionRetrospective StudiesRisk FactorsSystoleTetrazolesUnited StatesValineValsartanVentricular Dysfunction, LeftWhite PeopleConceptsLeft ventricular systolic dysfunctionHeart failureAcute myocardial infarctionMyocardial infarctionBaseline characteristicsAfrican AmericansMyocardial Infarction ComplicatedAngiotensin receptor blockersCoronary risk factorsOutcomes of patientsRecurrent myocardial infarctionVentricular systolic dysfunctionSimilar clinical outcomesHF hospitalizationCardiovascular morbidityCause mortalityReceptor blockersSystolic dysfunctionVentricular dysfunctionCardiovascular mortalityWhite patientsClinical outcomesPoor outcomeVALIANT trialSubgroup analysis
2007
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality
Thomas KL, Al-Khatib SM, Lokhnygina Y, Solomon SD, Kober L, McMurray JJ, Califf RM, Velazquez EJ. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American Heart Journal 2007, 155: 87-93. PMID: 18082495, DOI: 10.1016/j.ahj.2007.09.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmiodaroneCaptoprilCause of DeathDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProbabilityProportional Hazards ModelsReference ValuesRisk AssessmentSeverity of Illness IndexSurvival AnalysisTetrazolesTreatment OutcomeValineValsartanVentricular DysfunctionConceptsVentricular systolic dysfunctionAmiodarone useAcute myocardial infarctionMyocardial infarctionSystolic dysfunctionLeft ventricular systolic dysfunctionPost-acute myocardial infarctionHazard ratio 1.5Higher Killip classTrials of amiodaroneKillip classVentricular dysfunctionBaseline characteristicsCardiovascular mortalityDiabetes mellitusHeart failureMedical regimenRandomized comparisonBaseline predictorsExcess mortalityCox modelSubsequent mortalityDay 1PatientsAmiodarone
2004
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial
Jamerson K, Bakris G, Wun C, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez E, Weber M. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial. American Journal Of Hypertension 2004, 17: 793-801. PMID: 15363822, DOI: 10.1016/j.amjhyper.2004.05.004.Peer-Reviewed Original ResearchConceptsSystolic Hypertension (ACCOMPLISH) trialCardiovascular eventsBlood pressureHypertension trialsCombination therapyOptimal BP controlPrimary study endpointCalcium channel blockersClass of drugsBP controlCardiovascular outcomesHypertensive patientsPrimary endpointCardiovascular mortalityStudy endpointACE inhibitorsHypertension managementFirst patientClinical eventsAntihypertensive combinationsRisk factorsSuch therapyRecent guidelinesDrug classesVasculoprotective properties